deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03430011

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE)

Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma

Sponsor: Juno Therapeutics, a Subsidiary of Celgene

Conditions Multiple Myeloma
Interventions JCARH125 JCARH125 + anakinra
Updated 30 times since 2018 Last updated: Apr 29, 2024 Started: Feb 1, 2018 Primary completion: Mar 30, 2023 Completion: Mar 30, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Multiple Myeloma and is currently completed. Juno Therapeutics, a Subsidiary of Celgene leads this study, which shows 30 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Mar 2019 · 4 months · monthly snapshot~Mar 2019 – ~Aug 2019 · 5 months · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Jun 2022 · 9 months · monthly snapshot~Jun 2022 – ~Nov 2022 · 5 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Nov 2023 · 7 months · monthly snapshot~Nov 2023 – ~Jun 2024 · 7 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

30 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Nov 2023 — Jun 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  5. Apr 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 25 earlier versions

  1. Feb 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Dec 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Nov 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Jun 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Sep 2021 — Jun 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Apr 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

  9. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  10. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE1_PHASE2

  11. Sep 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

  12. Jun 2020 — Sep 2020 [monthly]

    Recruiting PHASE1_PHASE2

  13. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE1_PHASE2

  14. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE1_PHASE2

  15. Feb 2020 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

  16. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE1_PHASE2

  17. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE1_PHASE2

  18. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE1_PHASE2

  19. Aug 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  20. Mar 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  21. Nov 2018 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  22. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

  23. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  24. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1_PHASE2

  25. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Feb 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Juno Therapeutics, a Subsidiary of Celgene
Data source: Juno Therapeutics, a Subsidiary of Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Baltimore, United States , Birmingham, United States , Boston, United States , Buffalo, United States , Denver, United States , Detroit, United States , Duarte, United States , Hackensack, United States , Indianapolis, United States and 9 more locations